Dalpiciclib Plus Letrozole and Capecitabine
NCT05469750 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48
Last updated 2022-07-22
Summary
to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer
Conditions
Interventions
- DRUG
-
Dalpiciclib+ letrozole +capecitabine
Continue medication to disease progression
Sponsors & Collaborators
-
Fujian Medical University Union Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-10
- Primary Completion
- 2023-08-31
- Completion
- 2024-08-31
More Related Trials
-
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer
NCT06605690 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Dalpiciclib in HR+/HER2- ABC
NCT06301438 ·Status: RECRUITING
-
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
NCT06341894 ·Status: RECRUITING ·Phase: PHASE2
-
Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer
NCT04997798 ·Status: UNKNOWN ·Phase: PHASE2
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
NCT05806671 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
NCT05328440 ·Status: RECRUITING ·Phase: PHASE2
-
Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC
NCT06711094 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
NCT04460898 ·Status: COMPLETED
-
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546 ·Status: RECRUITING ·Phase: PHASE2
-
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
NCT02679755 ·Status: COMPLETED ·Phase: PHASE4
-
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
NCT02154776 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
NCT07117630 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
NCT07037199 ·Status: RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
NCT05431504 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
NCT05574881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
NCT06637150 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
NCT04524728 ·Status: COMPLETED
-
Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy
NCT07189884 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
NCT04927481 ·Status: TERMINATED ·Phase: PHASE2
-
Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC
NCT05505175 ·Status: COMPLETED
-
Treatment After Palbociclib-containing Regimens
NCT04517318 ·Status: COMPLETED
-
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
NCT06599216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
NCT06613373 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
NCT05586841 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1